Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice

P. Kosztyu, M. Kuchar, J. Cerny, L. Barkocziova, M. Maly, H. Petrokova, L. Czernekova, V. Liskova, L. Raskova Kafkova, P. Knotigova, J. Masek, J. Turanek, P. Maly, M. Raska,

. 2019 ; 47 (-) : 247-256. [pub] -

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005875

Grantová podpora
NV15-32198A MZ0 CEP - Centrální evidence projektů

BACKGROUND: The development of an effective vaccine preventing HIV-1 infection is hindered by the enormous antigenic variability and unique biochemical and immunological properties of HIV-1 Env glycoprotein, the most promising target for HIV-1 neutralizing antibody. Functional studies of rare elite neutralizers led to the discovery of broadly neutralizing antibodies. METHODS: We employed a highly complex combinatorial protein library derived from a 5 kDa albumin-binding domain scaffold, fused with support protein of total 38 kDa, to screen for binders of broadly neutralizing antibody VRC01 paratope. The most specific binders were used for immunization of experimental mice to elicit Env-specific antibodies and to test their neutralization activity using a panel of HIV-1 clade C and B pseudoviruses. FINDINGS: Three most specific binders designated as VRA017, VRA019, and VRA177 exhibited high specificity to VRC01 antibody. Immunized mice produced Env-binding antibodies which neutralize eight of twelve HIV-1 Tier 2 pseudoviruses. Molecular modelling revealed a shape complementarity between VRA proteins and a part of VRC01 gp120 interacting surface. INTERPRETATION: This strategy based on the identification of protein replicas of broadly neutralizing antibody paratope represents a novel approach in HIV-1 vaccine development. This approach is not affected by low immunogenicity of neutralization-sensitive epitopes, variability, and unique biochemical properties of HIV-1 Env used as a crucial antigen in the majority of contemporary tested vaccines. FUND: Czech Health Research Council 15-32198A, Ministry of Health, Czech Republic.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005875
003      
CZ-PrNML
005      
20201109104724.0
007      
ta
008      
200511s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2019.07.015 $2 doi
035    __
$a (PubMed)31544770
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kosztyu, Petr $u Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic.
245    10
$a Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice / $c P. Kosztyu, M. Kuchar, J. Cerny, L. Barkocziova, M. Maly, H. Petrokova, L. Czernekova, V. Liskova, L. Raskova Kafkova, P. Knotigova, J. Masek, J. Turanek, P. Maly, M. Raska,
520    9_
$a BACKGROUND: The development of an effective vaccine preventing HIV-1 infection is hindered by the enormous antigenic variability and unique biochemical and immunological properties of HIV-1 Env glycoprotein, the most promising target for HIV-1 neutralizing antibody. Functional studies of rare elite neutralizers led to the discovery of broadly neutralizing antibodies. METHODS: We employed a highly complex combinatorial protein library derived from a 5 kDa albumin-binding domain scaffold, fused with support protein of total 38 kDa, to screen for binders of broadly neutralizing antibody VRC01 paratope. The most specific binders were used for immunization of experimental mice to elicit Env-specific antibodies and to test their neutralization activity using a panel of HIV-1 clade C and B pseudoviruses. FINDINGS: Three most specific binders designated as VRA017, VRA019, and VRA177 exhibited high specificity to VRC01 antibody. Immunized mice produced Env-binding antibodies which neutralize eight of twelve HIV-1 Tier 2 pseudoviruses. Molecular modelling revealed a shape complementarity between VRA proteins and a part of VRC01 gp120 interacting surface. INTERPRETATION: This strategy based on the identification of protein replicas of broadly neutralizing antibody paratope represents a novel approach in HIV-1 vaccine development. This approach is not affected by low immunogenicity of neutralization-sensitive epitopes, variability, and unique biochemical properties of HIV-1 Env used as a crucial antigen in the majority of contemporary tested vaccines. FUND: Czech Health Research Council 15-32198A, Ministry of Health, Czech Republic.
650    _2
$a vakcíny proti AIDS $x imunologie $7 D016915
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a zvířata $7 D000818
650    _2
$a neutralizující protilátky $x krev $x imunologie $7 D057134
650    _2
$a antigeny virové $x chemie $x imunologie $7 D000956
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a epitopy $x chemie $x imunologie $7 D000939
650    _2
$a HIV protilátky $x krev $x imunologie $7 D015483
650    _2
$a HIV obalový protein gp120 $x imunologie $7 D015699
650    _2
$a HIV infekce $x imunologie $x virologie $7 D015658
650    _2
$a HIV-1 $x imunologie $7 D015497
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin G $x krev $x imunologie $7 D007074
650    _2
$a myši $7 D051379
650    _2
$a molekulární modely $7 D008958
650    _2
$a konformace proteinů $7 D011487
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kuchar, Milan $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic.
700    1_
$a Cerny, Jiri $u Laboratory of Structural Bioinformatics of Proteins, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic.
700    1_
$a Barkocziova, Lucia $u Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic.
700    1_
$a Maly, Michal $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic.
700    1_
$a Petrokova, Hana $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic.
700    1_
$a Czernekova, Lydie $u Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic.
700    1_
$a Liskova, Veronika $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic.
700    1_
$a Raskova Kafkova, Leona $u Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic.
700    1_
$a Knotigova, Pavlina $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic.
700    1_
$a Masek, Josef $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic.
700    1_
$a Turanek, Jaroslav $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic. Electronic address: turanek@vri.cz.
700    1_
$a Maly, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic. Electronic address: petr.maly@ibt.cas.cz.
700    1_
$a Raska, Milan $u Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic; Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic. Electronic address: milan.raska@upol.cz.
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 47, č. - (2019), s. 247-256
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31544770 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20201109104724 $b ABA008
999    __
$a ok $b bmc $g 1524733 $s 1095931
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 47 $c - $d 247-256 $e - $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
GRA    __
$a NV15-32198A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace